A look at current and potential treatment approaches for hormone receptor‐positive, HER2‐negative early breast cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34161
Abstract: The heterogeneity of hormone receptor (HR)‐positive, HER2‐negative early breast cancers reinforces the importance of individualized, risk‐adapted treatment approaches. Numerous factors contribute to the risk for recurrence, including clinical tumor features, individual biomarkers, and genomic risk.… read more here.
Keywords: her2 negative; treatment approaches; negative early; risk ... See more keywords
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-24-2113
Abstract: Abstract Purpose: Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present… read more here.
Keywords: ember study; cancer; breast cancer; her2 negative ... See more keywords
Abstract P4-11-03: Prediciting high risk hormone receptor (HR) positive Her-2 negative early breast cancer (BC) by artificial intelligence (AI) algorithms
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-p4-11-03
Abstract: Background: Genomic tests are needed in addition to clinical/pathological factors to optimize adjuvant treatment decisions in most patients with HR positive Her-2 negative early BC. We aimed to develop an AI-based model to predict high… read more here.
Keywords: positive negative; cancer; negative early; risk ... See more keywords
Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.522
Abstract: 522Background: Recent studies draw different conclusions concerning whether omission of anthracyclines (A) in adjuvant chemotherapy for HER2-negative early breast cancer (EBC) may reduce toxicity without compromising efficacy. Methods: The prospectively randomized PlanB and Success C… read more here.
Keywords: chemotherapy; early breast; breast cancer; negative early ... See more keywords
A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of thoracic disease"
DOI: 10.21037/jtd-21-1520
Abstract: Background We aimed to construct a clinical-radiomics nomogram to predict disease-free survival (DFS) and the added survival benefit of adjuvant chemotherapy (ACT) for node-negative, early-stage (I-II) lung adenocarcinoma (ADC). Methods In this retrospective study including… read more here.
Keywords: clinical radiomics; benefit; node negative; negative early ... See more keywords
A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0310
Abstract: Aim: To assess invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in hormone receptor-positive, HER2-negative early breast cancer with combined clinicopathological criteria from monarchE, a phase III study of abemaciclib. Methods: US electronic health records… read more here.
Keywords: early breast; her2 negative; negative early; breast cancer ... See more keywords